Literature DB >> 21147253

Aurora-A kinase inhibitor scaffolds and binding modes.

Aixia Yan1, Liyu Wang, Shuyu Xu, Jun Xu.   

Abstract

Aurora kinases (A-C) belong to the serine/threonine protein kinase family. In recent years, the constitutive or elevated expression of Aurora kinases has been found in cancer cells and oncogene transfected cells. In this review, we summarize the common binding modes of Aurora-A kinase inhibitors, the hot spot residues in the binding sites and the privileged inhibitor structures. Our review of the reported chemical scaffolds of Aurora-A kinase inhibitors and their binding modes could provide a useful framework from which new design strategies for inhibitors might be assessed or developed.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21147253     DOI: 10.1016/j.drudis.2010.12.003

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  9 in total

1.  Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.

Authors:  Scott R Plotkin; Jaishri O Blakeley; D Gareth Evans; C Oliver Hanemann; Theo J M Hulsebos; Kim Hunter-Schaedle; Ganjam V Kalpana; Bruce Korf; Ludwine Messiaen; Laura Papi; Nancy Ratner; Larry S Sherman; Miriam J Smith; Anat O Stemmer-Rachamimov; Jeremie Vitte; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2013-02-07       Impact factor: 2.802

2.  Benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one derivatives as Aurora A kinase inhibitors: LQTA-QSAR analysis and detailed systematic validation of the developed model.

Authors:  Ashish M Kanhed; Radha Charan Dash; Nishant Parmar; Tarun Kumar Das; Rajani Giridhar; Mange Ram Yadav
Journal:  Mol Divers       Date:  2015-07-17       Impact factor: 2.943

Review 3.  A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.

Authors:  Joost C M Uitdehaag; Folkert Verkaar; Husam Alwan; Jos de Man; Rogier C Buijsman; Guido J R Zaman
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 4.  Aurora A kinase (AURKA) in normal and pathological cell division.

Authors:  Anna S Nikonova; Igor Astsaturov; Ilya G Serebriiskii; Roland L Dunbrack; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2012-08-03       Impact factor: 9.261

5.  Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.

Authors:  Ning-Kui Niu; Zi-Li Wang; Shu-Ting Pan; Hui-Qiang Ding; Giang H T Au; Zhi-Xu He; Zhi-Wei Zhou; Guozhi Xiao; Yin-Xue Yang; Xueji Zhang; Tianxin Yang; Xiao-Wu Chen; Jia-Xuan Qiu; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2015-03-12       Impact factor: 4.162

6.  Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study.

Authors:  Guoxun Zheng; Weiwei Xue; Panpan Wang; Fengyuan Yang; Bo Li; Xiaofeng Li; Yinghong Li; Xiaojun Yao; Feng Zhu
Journal:  Sci Rep       Date:  2016-05-27       Impact factor: 4.379

Review 7.  On the molecular mechanisms of mitotic kinase activation.

Authors:  Richard Bayliss; Andrew Fry; Tamanna Haq; Sharon Yeoh
Journal:  Open Biol       Date:  2012-11       Impact factor: 6.411

8.  Integrity of p53 associated pathways determines induction of apoptosis of tumor cells resistant to Aurora-A kinase inhibitors.

Authors:  Yoshimi Shionome; Li Yan; Song Liu; Toshiaki Saeki; Toru Ouchi
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

9.  Specificity rendering 'hot-spots' for aurora kinase inhibitor design: the role of non-covalent interactions and conformational transitions.

Authors:  Preethi Badrinarayan; G Narahari Sastry
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.